Undue central nervous system (CNS) side effects including dysphoria and sedation remain
to be a challenge for the development of κ opioid receptor (KOR) agonists as effective and …

The search for selective kappa opioid receptor (κOR) agonists with an improved safety
profile is an area of interest in opioid research. In this work, a series of m-substituted analogs …

Research into kappa opioid receptor (KOR) agonists with attenuated central-nervous-system
side effects is a critical focus for developing productive and safe analgesics. Herein, a series …

κ opioid receptor (κOR) is a subtype of opioid receptors, and there are two major κOR
agonists currently available, morphinans and arylacetamides, which are structurally distinct …

The κ opioid receptor (KOR) is one of the promising targets to develop analgesics lacking
morphine like side effects. To seek a novel KOR agonist we designed 6-amide derivatives …

Abstract SLL-039 (N-cyclopropylmethyl-7α− 4′-(N'-benzoyl) amino-phenyl-6, 14-
endoethano-tetrahydronorthebaine) and SLL-1206 (N-cyclopropylmethyl-7α− 3′-(p …

We designed and synthesized the 1, 3, 5-trioxazatriquinane derivatives with m-
hydroxyphenyl groups. These compounds include the phenethylamine structure within them …

To develop novel analgesics with no side effects or less side effects than traditional opioids
is highly demanded to treat opioid receptor mediated pain and addiction issues. Recently, κ …

Aim: The aim of this study was to identify κ-opioid receptor (KOR) agonists from a library of
80 000 small-molecule compounds and provide the experimental basis for the development …

A novel 6, 14-epoxymorphinan benzamide derivative (NS22) that was previously reported
showed opioid κ receptor agonistic activity and analgesic activity. The unsatisfactory κ …